Last updated: September 27, 2022
Sponsor: Centre Hospitalier Universitaire de la Réunion
Overall Status: Active - Recruiting
Phase
N/A
Condition
Nephropathy
Treatment
N/AClinical Study ID
NCT02812212
2015/CHU/11
Ages 4-8 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Infants:
- Aged of 4 to 8 weeks of life
- Presenting an ureteropelvic junction obstruction (UPJO) detected before birth byultrasound
- Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater orequal to 15 mm, confirmed by ultrasound post-natally between the 1st and 15th day oflife
- Presenting a unilateral UPJO
- whose legal representatives have provided a signed free and informed written consentfor their infant's participation
- whose at least one of his legal representative is affiliated to national socialsecurity
Exclusion
Exclusion Criteria: Infants presenting:
- A bilateral UPJO
- An ureteral dilatation
- An associated contralateral uropathy
- A solitary kidney
- A renal insufficiency
- Severe associated disabilities ( ie polymalformation syndromes)
- A concomitant participation in another trial
- A contraindication to furosemide (acute renal insufficiency, hepatic encephalopathy,hypovolemia or dehydration, severe hypokalemia, severe hyponatremia)
- A contraindication to the radionuclide marker (hypersensitivity to the activesubstance or to excipients)
Study Design
Total Participants: 75
Study Start date:
November 28, 2017
Estimated Completion Date:
April 30, 2027
Study Description
Connect with a study center
CHU de Bordeaux
Bordeaux, 33076
FranceActive - Recruiting
CHU de Limoges
Limoges, 87000
FranceActive - Recruiting
CHU de Nantes
Nantes, 44000
FranceSite Not Available
CHU de Rennes
Rennes, 35023
FranceSite Not Available
Centre Hospitalier Universitaire de La Réunion
Saint-Denis, 97400
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.